Compare Brunswick Corporation (BC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brunswick Corporation vs Merck & Co., Inc. — how do they compare? Brunswick Corporation trades at $77.96 (market cap $5.04B), while Merck & Co., Inc. trades at $124.68 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 59.2× Brunswick Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals.
| BC | MRK | |
|---|---|---|
Market Cap | $5.04B | $298.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $89.22 | $129.52 |
52-Week Low | $56.64 | $77.60 |
Enterprise Value | $7.20B | $341.72B |
Dividend Yield | 2.27% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BC's stock trades at $76.95, down 1.22% on the day, with a bearish technical signal and support near $76. The company reported a net loss of $137.30 million in 2025 despite revenue of $5.36 billion, though recent earnings beat expectations. Analyst consensus is strongly bullish with a $86.40 price target, and the company continues expanding its Freedom Boat Club business.
The outlook is mixed: strong analyst support and operational cash flow of $562.10 million in 2025 provide upside potential, but negative profit margins and high P/E of 73.92 pose valuation risks. Investors face headwinds from profitability challenges despite positive sentiment from Wall Street.
Merck (MRK) trades at $124.34, showing modest daily gains of 0.25% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with 73.91% gross margins and has beaten earnings expectations in recent quarters. Recent acquisition activity, including the Terns Pharmaceuticals deal announced April 7, 2026, demonstrates strategic pipeline expansion in oncology.
Merck presents a compelling investment case with analyst consensus favoring bullish sentiment (67.57% buy ratings) and a $137.30 price target offering ~10% upside. However, rising debt levels and projected 2026 earnings decline warrant caution. The stock's premium valuation at 34x P/E requires sustained execution to justify current pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
